optiNAVO: A Phase II, Randomized, Open-label Study Evaluating Two Invaolisib Dose Levels in Combination With Fulvestrant in Participants with PIK3CA-mutated, HR-postive, HER2-negative Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer


Go To Trial Homepage